In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
After finishing at $3.41 in the prior trading day, Arbutus Biopharma Corp (NASDAQ: ABUS) closed at $3.37, down -1.17%. In other words, the price has decreased by -$1.17% from its previous closing price. On the day, 1.81 million shares were traded. ABUS stock price reached its highest trading level at $3.475 during the session, while it also had its lowest trading level at $3.365.
Ratios:
Our goal is to gain a better understanding of ABUS by taking a closer look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 6.01 and its Current Ratio is at 6.01. In the meantime, Its Debt-to-Equity ratio is 0.07 whereas as Long-Term Debt/Eq ratio is at 0.06.
On February 25, 2021, Jefferies started tracking the stock assigning a Hold rating and target price of $5.
On December 17, 2020, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $10.H.C. Wainwright initiated its Buy rating on December 17, 2020, with a $10 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Apr 21 ’25 when McElhaugh Michael J. bought 246,886 shares for $3.26 per share.
McElhaugh Michael J. bought 53,114 shares of ABUS for $170,098 on Apr 15 ’25. On Mar 31 ’25, another insider, Sofia Michael J., who serves as the Officer of the company, bought 250,000 shares for $3.50 each.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABUS now has a Market Capitalization of 645446016 and an Enterprise Value of 538337408. For the stock, the TTM Price-to-Sale (P/S) ratio is 100.85 while its Price-to-Book (P/B) ratio in mrq is 8.15. Its current Enterprise Value per Revenue stands at 84.076 whereas that against EBITDA is -8.134.
Stock Price History:
The Beta on a monthly basis for ABUS is 1.24, which has changed by 0.11960137 over the last 52 weeks, in comparison to a change of 0.11213791 over the same period for the S&P500. Over the past 52 weeks, ABUS has reached a high of $4.72, while it has fallen to a 52-week low of $2.70. The 50-Day Moving Average of the stock is 0.78%, while the 200-Day Moving Average is calculated to be -4.30%.
Shares Statistics:
The stock has traded on average 921.43K shares per day over the past 3-months and 779950 shares per day over the last 10 days, according to various share statistics. A total of 191.48M shares are outstanding, with a floating share count of 148.66M. Insiders hold about 22.38% of the company’s shares, while institutions hold 58.84% stake in the company. Shares short for ABUS as of 1748563200 were 12751934 with a Short Ratio of 13.84, compared to 1745971200 on 11190235. Therefore, it implies a Short% of Shares Outstanding of 12751934 and a Short% of Float of 9.46.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
